AUAUniversity

Quentin Clemens, MD

Professor of Urology

University of Michigan Medical Center

Patrick Hamilton of CMS explains changes to the 2020 Merit-based Incentive Payment System (MIPS) and how this impacts reporting. Additionally, he answers questions from the audience highlighting issues important to urologic practices.

Dr. Eugene Rhee discusses getting your practice up and running with telemedicine on today's podcast. Dr. Rhee's comments include special considerations given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States.

Dr. Chris Gonzalez discusses considerations for elective urologic surgery given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States. Dr. Gonzalez is chair of the AUA Public Policy Council.

For more information, please visit the AUA's COVID-19 Information Center. https://www.auanet.org/covid-19-info-center

E.R. Mueller, MD, MSME - Loyola University Chicago

Joseph C. Liao, MD - Stanford University

J. Curtis Nickel, MD, FRCSC - Queen's University

Daniel Shoskes, MD, FRCSC - Cleveland Clinic

This episode provides an introduction to the Urologic Diseases in America (UDA) Report and features perspectives from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine

Guest: Kevin Abbott, MD, MPH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health

This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.

Michel Pontari, MD

Lewis Katz school of Medicine at Temple University

AUA2019 Virtual Meeting available now: https://auau.auanet.org/content/aua2019-chicago-virtual-meeting-2019

CME Available: https://auau.auanet.org/node/27477

Course Director:

Eric Rovner, MD

Faculty:

Kathleen Kobashi, MD

Sandip Vasavada, MD

At the conclusion of this activity, participants will be able to:

1. Define the similarities and differences between the various pharmacotherapies for OAB.

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.

3. Realize the importance of setting proper patient expectations regarding treatment of OAB and potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.

This educational series is supported by an independent educational grant from:

Astellas

Moderator

John Brock, III, MD

Professor and Director, Division of Pediatric Urology

Debater - Pro(s)

Richard Yu, MD,PHD

Harvard Medical School

Mohan Gundeti, MD

The University of Chicago

Debater - Con(s)

Linda Baker, MD

Professor of Urology

The University of Texas Southwestern

H. Rushton, Jr., MD

Children's National Medical Center-The George Washington University Medical Center

Moderator(s)

Jeremy Myers, MD

University of Utah

Debater - Pro(s)

Hunter Wessells, MD, FACS

Professor and Chair

University of Washington School of Medicine

Reynaldo Gomez, MD

Hospital del Trabajador

Debater - Con(s)

Steven Brandes, MD

Columbia University Medical Center

Jill Buckley, MD, FACS

University of California, San Diego

Moderator:

Seth Cohen, MD

Panelists:

Gina Badalato, MD

Kathleen Kieran, MD

Kyle Zuniga (MS4)

Vincent D'Andrea (MS4)